Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 18 (1) , 57-82
- https://doi.org/10.2165/00002018-199818010-00005
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- A Study of Fluoxetine in Obese Elderly Patients with Type 2 DiabetesDiabetic Medicine, 1995
- Comparative Efficacy of AntidepressantsDrugs, 1992
- Pharmacological Differences of Serotonin Reuptake Inhibitors and Possible Clinical RelevanceDrugs, 1992
- AntidepressantsDrugs, 1989
- Fluvoxamine and Imipramine: Results of a Long-term Controlled TrialInternational Clinical Psychopharmacology, 1987
- The economic burden of depressionGeneral Hospital Psychiatry, 1986
- Management of poisoning associated with “newer” antidepressant agentsAnnals of Emergency Medicine, 1986
- Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptorsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- Post-stroke depressive disorders: a follow-up study of 103 patients.Stroke, 1982